snk01
snk01: sourced relationships with 1 company · 2 clinical trials tracked.
snk01 evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could snk01 → NKGN affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| NKGen Biotech, Inc. (NKGN) Moderate Alzheimer Disease; Alzheimer Disease | Phase 1/Phase 2 |
Clinical Trial Registry Records (2)
An Open-Label Extension (OLE) Study to Evaluate the Long-Term Safety, Tolerability and Exploratory Efficacy of SNK01 in Participants With Alzheimer's Disease (Study SNK01-AD02)
Primary endpoint: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
A Phase I/IIa, Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of SNK01 in Participants With Moderate Alzheimer's Disease
Primary endpoint: Number of participants with dose-limiting toxicity
Frequently asked questions
Which companies have sourced relationships with snk01?
snk01 has dated SEC/FDA relationship records for NKGen Biotech, Inc..
How many clinical trials involve snk01?
BioSniper tracks 2 clinical trials involving snk01.